阿替普酶联合氯吡格雷治疗急性脑梗死疗效观察

Clinical Efficacy Observation of Alteplase Combined with Clopidogrel in the Treatment of Acute Cerebral Infraction

目的探讨阿替普酶静脉溶栓联合氯吡格雷治疗急性脑梗死的疗效。方法选择2021年1月至2022年1月收治的急性脑梗死患者84例,随机分为两组,各42例。对照组采用阿替普酶静脉溶栓治疗,研究组采用阿替普酶静脉溶栓联合氯吡格雷治疗,两组均治疗1周。结果研究组总有效为97.62%,显著高于对照组的83.33%(P<0.05);治疗后,研究组患者NIHSS评分、临床指标(高密度脂蛋白胆固醇和同型半胱氨酸水平)、生活质量评分均显著优于对照组(P<0.05)。研究组和对照组患者治疗期间药品不良反应发生率相当(7.14%比9.52%,P>0.05)。结论阿替普酶静脉溶栓联合氯吡格雷治疗急性脑梗死疗效显著,可有效改善神经功能缺损,值得临床推广。

Objective To investigate the clinical efficacy of alteplase combined with clopidogrel in the treatment of acute cerebral infraction.Methods A total of 84 patients with acute cerebral infraction treated in the hospital from January 2021 to January 2022 were selected and randomly divided into two groups,with 42 cases in each group.The patients in the control group were given alteplase intravenous thrombolysis treatment,on this basis,the patients in the study group were given clopidogrel treatment.Both groups were treated for one week.Results The total effective rate of the study group was 97.62%,which was significantly higher than 83.33%of the control group(P<0.05).After treatment,the National Institutes of Health Stroke Scales(NHISS)score,clinical indexes(the levels of HDL cholesterol and homocysteine)and the score of life quality in the study group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions in the study group was similar to that in the control group(7.14%vs.9.52%,P>0.05).Conclusion Alteplase intravenous thrombolysis combined with clopidogrel in the treatment of acute cerebral infraction has a significant efficacy.It can improve the nerve function defect,which is worthy of clinical promotion.